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Abstract
The objectives of this work were to express the EC5 domain of E-cadherin and determine its
structural characteristics as well as to evaluate the binding properties of HAV and BLG4 peptides
to EC5 using spectroscopic methods. Homophilic interactions of E-cadherins are responsible for
cell-cell adhesion in the adherens junctions of the biological barriers (i.e., intestinal mucosa and
blood-brain barriers). The EC5 domain of E-cadherin has an important role in T-cell adhesion to
intestinal mucosa via αEβ7 integrin-E-cadherin interactions. In this study, the expressed EC5 has a
high thermal stability (Tm = 64.3 °C); it also has two stable conformations at room temperature,
which convert to one conformation at approximately 54.5 °C. NMR and FTIR showed that HAV
and BLG4 peptides bind to EC5. HSQC-NMR showed that either Asn or Gln of EC5 was involved
in the interactions with HAV and BLG4 peptides. EC5 underwent a conformational change upon
interaction with the HAV and BLG4 peptides. Finally, the binding properties of both peptides
were modeled by docking experiments, and the results suggest that Asn-46 and Asn-75 of EC5
could be involved during the interaction with the peptides and that the Ser and Trp residues of the
HAV and BLG4 peptides, respectively, were important for binding to EC5.
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INTRODUCTION
E-cadherins are glycoproteins that create calcium-dependent cell-cell adhesion at the
adherens junctions of biological barriers (i.e., the intestinal mucosa and the blood-brain
barrier) (1) and have an important role in cell morphogenesis, tumor invasion and metastasis
(2, 3). The extracellular (EC) domain of E-cadherin consists of five repeats, EC1 to EC5
domains that have been suggested to form homophilic interactions. The structures of various
repeats of the EC domain of E-, N-, and C-cadherins have been studied by NMR, X-ray,
electron microscopy, and surface force apparatus (4–9). The results from various studies
generated two possible major mechanisms, one of which involves only EC1-EC1
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interactions (10–13) while the other involves interactions of all the EC domains (EC1
through EC5). However, there are no available data that can reconcile these two major
mechanisms. The X-ray structure of C-cadherin suggests that the trans-dimer of cadherins is
formed by the interaction only between two EC1 domains from the opposing membranes,
while the cis-interaction is between the EC1 and EC2 domains of two molecules from the
same surface (14). However, surface force measurements and binding studies of truncated
domains of C-cadherin suggest that trans-interactions between cadherins from opposing
cells are caused by interdigitized multidomain interactions (7, 15–17). If this is the case, it is
important to study the structure of the other domains of E-cadherin (i.e., EC3, EC4, and
EC5) and their roles in E-cadherin-E-cadherin interactions.
The interaction between E-cadherin and αEβ7-integrin during T-cell adhesion to the
intestinal epithelium involves EC1 and EC5 domains of E-cadherins (18, 19). Thus,
elucidation of the structure and interaction properties of the EC5 domain could provide
information for designing a selective way to modulate E-cadherin-mediated cell-cell
adhesion for therapeutic purposes such as improving drug delivery and controlling
inflammation. We also have shown that peptides derived from E-cadherin (i.e., HAV
peptides) enhance the paracellular permeation of a marker molecule (i.e., 14C-mannitol)
through Madin-Darby Canine Kidney (MDCK) cell monolayers (13, 20, 21). The peptide
activity may be due the inhibition of E-cadherin interactions in the intercellular junctions.
Thus, characterization of the peptide-binding to EC domains is necessary to improve the
activity of E-cadherin peptides in modulating E-cadherin-mediated cell-cell adhesion.
In this work, the EC5 domain of E-cadherin was expressed and its structural properties were
evaluated using spectroscopic methods (i.e., circular dichroism (CD), UV absorbance,
Fourier transform infrared (FTIR), intrinsic fluorescence, and NMR spectroscopy, and
differential scanning calorimetry (DSC). EC5 has the potential to inhibit homotypic cell-cell
adhesion and heterotypic T-cell adhesion. The unique structure of EC5 with two disulfide
bonds is a good model for studying the role of disulfide bonds on its structural stability. The
binding properties of the HAV (Ac-SHAVSS-NH2) and BLG4 (Ac-TYRIWRDTAN-NH2)
peptides to the EC5 domain of E-cadherin were also studied using FTIR and NMR
spectroscopy. These two peptides appear to induce a conformational change in EC5 upon
binding. Finally, computational docking experiments were performed to provide working
models for the interaction between each peptide and EC5. In the future, these binding
models will be used to design small peptide derivatives that effectively modulate the
intercellular junctions of the in vitro and in vivo models of the biological barriers (i.e.,
intestinal mucosa and blood-brain barriers).
EXPERIMENTAL METHODS
Recombinant EC5 plasmid construction
Construction of the pASK-IBA6/EC5 plasmid—The method used to clone the gene
for EC5 is similar to that employed for the EC4 domain (22). Full-length human E-cadherin
cDNA cloned in pERF-cadherin was provided by Dr. David Rimm of Yale University. Both
forward and reverse primers contain the BsaI restriction site. A standard PCR program was
used to amplify EC5 cDNA, and the expression vector pASK-IBA6 (Sigma-Genosys,
Woodlands, TX) was digested with 15 units of BsaI. The BsaI-digested EC5 cDNA was
cloned downstream of the OmpA signal peptide, Strep-Tag II, and the Factor Xa site of the
vector using T4 ligase (Promega, Madison, WI). The recombinant plasmid pASK-IBA6/EC5
was transformed into competent E. coli BL21 cells (Stratagene, La Jolla, CA) using a heat
pulse at 42 °C for 45 s. The transformed cells were grown overnight at 37 °C on LB plates
containing 100 µg/mL ampicillin. The positive clones were screened by PCR, and the EC5
cDNA sequence was confirmed by DNA sequencing.
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Construction of the pET24d/EC5 plasmid—To improve the yield of EC5, we
developed a new expression plasmid. The forward primer contains an NcoI restriction site
and the reverse primer an XhoI site. A standard PCR program was used with the following
conditions: 94 °C for 2 min; 30 cycles of 94 °C for 1 min, 55 °C for 1 min, and 72 °C for 1
min; and, finally, 72 °C for 10 min. The PCR amplification was performed using 5 µL of 5
µM forward and reversed primers, 2 µL of 50 ng/µL full-length cDNA, 200 µM dNTP, 28
µL of distilled water, 5 µL of 10X PCR buffer (Stratagene), and 1 µL Pfu Turbo Polymerase
(Promega). After PCR, the purified EC5 cDNA and the pET24d vector (Novogen, Madison,
WI) were digested with NcoI and XhoI. The digested products were ligated using T4 ligase
(Promega). After ligation, pET24d/EC5 was inserted into the high expression vector pET24d
(Novogen). The recombinant plasmid pET24d/EC5 was then transformed into competent E.
coli BL21 cells (Stratagene) using a heat pulse at 42 °C for 45 s. The transformed cells were
grown overnight at 37 °C on LB plates containing 30 µg/mL kanamycin. The correct EC5
cDNA sequence was confirmed by DNA sequencing.
Expression and purification of recombinant EC5
Production of Strep-Tag II-containing EC5 (pASK-IBA6/EC5)—The expression and
purification of EC5 was performed in a manner similar to a previously described method
(22). E. coli cells were cultured in 250 mL of 2-X YT medium with 100 mg/L of ampicillin
and then induced with 25 µL (200 µg/L) anhydrotetracycline (Sigma-Genosys). After
induction, cells were collected every hour and lysed. The whole-cell lysates were analyzed
by SDS-PAGE. An intense protein band was produced with the expected size of Strep-Tag
II fused-EC5. The optimal expression of EC5 was reached after 3 h of induction.
Recombinant EC5 was found in the supernatant after cell lysis. The EC5 protein was
subjected to a one-step purification using a Strep-Tactin affinity column. The affinity-
purified EC5 fractions were analyzed by 4–20% SDS-PAGE; they produced a single band at
the correct molecular weight for EC5 and an optimal yield of 0.5 mg/L.
Production of EC5 without Strep-Tag (pET24d/EC5)—For producing the EC5
domain without a Strep-Tag at the N-terminus, E. coli BL21/pET24d-EC5 cells were
inoculated in 500 mL 2-X YT medium with 30 mg/L of kanamycin at 37 °C using a 200 rpm
shaking incubator followed by concentration measurements every 1 or 2 h. The optical
density (OD) of the culture was measured at 600 nm. When the OD value was between 0.6
and 0.8 (2.5 to 3 h), 0.5 mL of 100 mg/mL isopropyl β-D-thiogalactoside (IPTG) (Sigma-
Aldrich, Milwaukee, WI) was added to initiate the over expression. The culture was over
expressed for 4 h and harvested by centrifugation at 4000 × g at 4 °C for 10 min. The
resulting pellets were kept at −80 °C overnight.
On the following day, the cell pellets were thawed and resuspended in 10 mL of 50 mM
Tris-HCl and 100 mM NaCl buffer at pH 7.5, then lysed using a French Press. The cell
lysate was centrifuged at 48000 × g and 4 °C in a Beckman JA 20 rotor for 45 min, after
which the majority of the EC5 was found in the supernatant. To purify the EC5 domain, a
heat/cool cycle was used to remove most of the E. coli proteins. Because there are two
intramolecular disulfide bonds, EC5 is relatively thermally stable and its temperature-
induced conformational change is reversible. The supernatant was therefore incubated at 80
°C for 10 min and then in ice for 5 min (23). EC5 remained soluble in the supernatant. The
supernatant was dialyzed in a 50 mM Tris buffer at pH 7.5 overnight. After dialysis, the
protein solution was centrifuged at 48000 × g and 4 °C in a Beckman JA 20 rotor for 30
min. The supernatant was loaded onto a Q-sepharose anion exchange column (Amersham
Biosciences, Piscataway, NJ). The following buffers were used for the gradient elution.
Buffer A contained 50 mM Tris-HCl at pH 7.5 and buffer B 50 mM Tris-HCl and 1 M NaCl
at pH 7.5. After elution from the Q-sepharose column, the fractions containing EC5 were
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collected, concentrated, and loaded onto a Superdex 200 size-exclusion column (Amersham
Biosciences) for final purification. The fractions containing EC5 were collected and loaded
onto a 4–20% SDS-PAGE gel. The final purity of the EC5 domain was greater than 99%
based on reversed-phase HPLC analysis. A Shimadzu (Shimadzu, Columbia, MD) 10A VP
HPLC system containing a Vydac 208TP C8 column (Grace Vydac, Hesperia, CA) with 4.6
mm diameter and 25 cm length was used. The flow rate was 1 mL/min with a 60-min
running time. The injection volume was 10 µL. The detection wavelength was 280 nm and
the retention time was 52.6 min. The optimal yield of EC5 in 2-X YT medium was 5–10 mg/
L.
15N-labeled EC5 was used in binding studies between the peptide and EC5. One set of
binding properties was monitored using 1H, 15N 2D-HSQC NMR spectroscopy. To
produce 15N-labeled EC5, E. coli cells containing EC5 cDNA were cultured in 15N-labeled
minimal medium (M9) containing 13 g Na2HPO4·7H2O, 3 g KH2PO4, 0.5 g NaCl, 1
g 15NH4Cl (Cambridge Isotope, Andover, MA), 2.2 g MgSO4·7H2O, and 0.7 g CaCl2·2H2O
per liter. The pH of the final medium was adjusted to 7.4 using 5.0 N HCl. Prior to
inoculation, the M9 medium was supplemented with freshly prepared 20% D-glucose, 1 ×
10−3 mM thiamine, 1 × 10−3 mM FeSO4·7H2O, and 30 mg/L of kanamycin. Over
expression and purification methods for the labeled EC5 were the same as employed for
unlabeled EC5. The final purified protein had a concentration of 0.5 mM in 100 mM Tris
buffer at pH 7.5.
15N,13C double-labeled EC5 was used to study peptide binding by monitoring changes in
the amide I band using FTIR. The same method described above was used to
produce 15N,13C double-labeled EC5. In this case, 13C-labeled D-glucose (Spectra Stable
Isotopes, Columbia, MD) was utilized instead of unlabeled D-glucose. After
purification, 15N,13C double-labeled EC5 was concentrated to 0.5 mM in 100 mM Tris
buffer at pH 7.5.
Structural studies of EC5 and binding properties to E-cadherin peptides
Characterization of disulfide bonds—Twenty µL each of 10 µM native and reduced
EC5 in 25 mM Tris buffer at pH 7.5 were added to 75 µL of 8.0 M guanidinium
hydrochloride (Gdn.HCl). This mixture was shaken for 10 s to unfold the EC5 protein. Five
µL of 200 µM ThioGlo-1 was added, and the mixture was incubated for 30 min at room
temperature. The amount of free thiol was detected by determining the amount of
incorporated fluorescence label in the ThioGlo-1 reaction (24). Twenty µL of 25 mM Tris
buffer at pH 7.5 received the same treatment and was used as a blank. The fluorescence
intensity was detected using a BioTek FL600 microplate fluorescence reader (BioTek
Instruments, Winooski, VT) with an excitation wavelength of 360 nm and emission detected
at 530 nm.
Size-exclusion chromatography (SEC)—SEC was performed with a 24 mL Superdex
200 column (Amersham Biosciences) using UV absorbance detection at 280 nm. The mobile
phase was 25 mM Tris-HCl (pH 7.5) with a flow rate of 0.4 mL/min. The standard protein
kit was used for calibration.
CD spectroscopy—CD spectra of EC5 were obtained from 250 nm to 200 nm using a
J-810 CD spectrometer (Jasco, Easton, MD) at room temperature. Four hundred µL of 0.02
mM EC5 in various buffers were loaded into a 0.1 cm path-length cell. The spectra were
averaged over three repetitive scans with data acquired every 0.5 nm with a 2-s response
time (25, 26). The corresponding buffer was scanned as a blank and subtracted. The
secondary structure of EC5 in 0.02 mM EC5 in 25 mM Tris buffer at pH 7.5 was estimated
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using the Selcon3 program (27). The temperature-induced unfolding of EC5 was monitored
at a fixed wavelength of 230 nm. The temperature was varied from 10 to 90 °C with data
taken in 0.2 °C increments and a heating rate of 15 °C/h. For temperature studies, EC5 was
examined in 25 mM K2HPO4 buffer at pH 7.5. The melting temperature of EC5 was
estimated by Sigmoidal fit in Microcal Origin 6.0.
FTIR spectroscopy—EC5 was concentrated to 1.6 mM in 25 mM Tris at pH 7.5 in the
presence and absence of 2.5 mM DTT for analysis by FTIR spectroscopy. FTIR spectra
were acquired employing a Nicolet Magna-IR 560 spectrometer with a mercury-cadmium-
telluride (MCT) detector. The EC5 protein was placed between CaF2 transmittance windows
using a 5.6 µm spacer. The reference sample was 25 mM Tris buffer at pH 7.5 and was run
under identical conditions. Two hundred and fifty-six consecutive scans were collected for
each sample at a resolution of 2 cm−1. The water signal was subtracted from each spectrum
using the criterion of a straight baseline between 2000 and 1700 cm−1. Omnic E.S.P. 4.1
software was used to smooth the original spectra. GRAMS/AI (7.00) was used to calculate
derivative spectra. A mixed Lorentzian and Gaussian function was used for curve fitting
(28). Correlation coefficients (r = ∑ xiyi/√ ∑ xi2∑ yi2) were used to evaluate the difference
between the second derivative spectra of native and reduced EC5 (29). xi and yi represent
the second derivative values of native and reduced EC5 spectra at each frequency,
respectively.
Binding between the peptide (HAV, Ac-SHAVSS-NH2 or BLG4, Ac-TYRIWRDTAN-
NH2) and EC5 was evaluated by observing the change in the FITR spectra of 15N,13C-
labeled EC5 in the absence and presence of the peptide. Binding experiments were
conducted in 100 mM Tris buffer in D2O at pH 7.5. In this case, 50 mM HAV or 25 mM
BLG4 was added to a 0.5 mM solution of labeled EC5. The sample was introduced into a
calcium fluoride transmittance window with a 0.5 mm pathlength. Spectra were collected
using a Nicolet Magna-IR 560 spectrometer with a MCT detector. The detector was cooled
with liquid nitrogen during data collection. The FTIR spectrum of unlabeled EC5 was also
collected for comparison. Two hundred and fifty-six consecutive scans were collected for
each sample with a resolution of 2 cm−1. The buffer signal was subtracted from each
spectrum using a straight baseline between 1900 cm−1 and 1700 cm−1. Omnic E.S.P. 4.1
software (Nicolet, Madison, WI) was used to smooth the original spectra. Derivative spectra
from 1700 cm−1 to 1500 cm−1 were calculated using GRAMS/AI (7.00). Curve fitting was
performed using a mixed Lorentzian and Gaussian function between 1647 cm−1 and 1563
cm−1 in Omnic software (Nicolet) (28). The number and position of the deconvoluted peaks
were determined from the second derivative trace of the amide I band.
High-resolution second derivative UV absorbance spectroscopy—UV spectra
were recorded using a Hewlett-Packard 8453 UV-visible spectrophotometer (Agilent, Palo
Alto, CA). One mL of 0.02 mM purified EC5 in a 25 mM phosphate buffer at pH 7.5 was
loaded into a 1-cm pathlength quartz cuvette. Spectra were obtained over the temperature
range of 10 to 85 °C at 2.5 °C intervals using a 5-min equilibration period before data
acquisition. Agilent UV-visible Chemstation software was used to calculate second
derivatives; data were processed as described previously, and Microcal Origin 6.0 was used
to plot the data (30, 31).
Differential scanning calorimetry (DSC)—DSC was performed with a Nano-DSC
calorimeter (Calorimetry Sciences Corp., American Fork, UT). The pure EC5 protein in a 25
mM phosphate buffer at pH 7.5 (1.2 mL of a 0.1 mM solution) was injected into the sample
cell while 1.2 mL of 25 mM phosphate buffer at pH 7.5 was placed in the reference.
Thermograms were obtained from 10 to 100 °C with a scan rate of 60 °C/h. Microcal Origin
6.0 software was used for curve fitting (28).
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Fluorescence spectroscopy—Intrinsic fluorescence emission spectra were collected
with a QuantaMaster spectrofluorometer (PTI, Monmouth Junction, NJ). One and one-half
mL of 0.02 mM EC5 in a 25 mM phosphate buffer at pH 7.5 was loaded into a 1-cm
pathlength quartz fluorescence cuvette. Spectra were collected from 10 to 80 °C at 2.5 °C
intervals. A 5-min equilibration was performed before each collection of spectra. The
excitation wavelength was set at 295 nm (>95% Trp emission), and emission was monitored
from 305 to 455 nm. The excitation and emission slits were set at 4 nm. The Felix program
was used to analyze the data (32, 33).
NMR spectroscopy—To establish conditions for structural analysis by NMR, 15N-
labeled EC5 was dissolved in 25 mM Tris buffer at pH 7.5 and 1H-15N 2D HSQC spectra
were collected using a Bruker Avance 800 MHz NMR spectrometer (Bruker BioSpin Corp.,
Billerica, MA) equipped with a TCI triple-axis gradient cryoprobe. D2O (2%) was added to
each sample to provide the lock signal. These spectra were acquired at 5 °C temperature
intervals from 10 to 65 °C with 5-min equilibration prior to the start of each experiment.
Each spectrum was signal averaged over 16 scans in which 1024 points were collected in 1H
and 128 points in 15N, and referencing was performed relative to DSS (34). Spectra were
processed using nmrPipe (35).
For peptide binding studies, 1H-15N-HSQC spectra of 0.2 mM 15N-labeled EC5 in 5% D2O
in the absence or presence of 20 mM HAV or 10 mM BLG4 were acquired in 100 mM Tris
buffer at pH 7.5 using a Bruker Avance 800 MHz NMR spectrometer equipped with a TCI
triple-axis gradient cryoprobe. Sixteen consecutive scans were collected and averaged for
each spectrum. One thousand and twenty four points were obtained in the direct detect
dimension (1H) and 128 increments were collected for 15N. Referencing was performed
relative to DSS (34). After collection, all data were analyzed by nmrPipe (35).
Computational docking—The structural model of the EC5 domain of E-cadherin was
generated by homology modeling using the EC5 domain of C-cadherin (PDB entry 1L3W)
as a template (14). In addition, all publically available cadherin crystal structures, including
C-cadherin (pdb entry 1L3W), N-cadherin (pdb entries 1NCH, 1NCI, 1NCG) and E-
cadherin (pdb entry 1EDH), and a modeled structure of the EC5 domain of E-cadherin were
initially used to characterize structural space of cadherins. These structures were minimized
and superimposed into a common reference frame is based on similarity of Cα atoms for a
common set of residues from the bulge and groove protein regions. The peptide
conformations were generated using molecular modeling software MACROMODEL and
minimized using AMBER* force field. Conformational search for the low—energy peptide
conformations was performed within MACROMODEL modeling tool, utilizing Monte
Carlo conformational search with an energy window of 6.0 kcal/mole and up to 1000 Monte
Carlo steps. Minimization is performed using AMBER* force field with the Generalized
Born/Solvent Accessible Surface Area (GB/SA) salvation term. We have employed a
modeling approach, in which structure and energetics of peptide binding can be effectively
interrogated using fully automated flexible peptide docking with ensembles of multiple
protein structures (36–39). The molecular recognition energetic model includes
intramolecular energy terms, given by torsional and nonbonded contributions and the
intermolecular energy contributions calculated using the AMBER force field to describe
peptide–protein interactions combined with an implicit solvation model (36–39). Molecular
docking was performed using simulated tempering sampling technique with the ensemble of
multiple protein structures. The peptide conformations and orientations were sampled in a
parallelepiped that encompasses the superimposed structures with a 10.0 Å cushion added to
every side of the box surrounding the binding interface, which guaranteed an unbiased
search of the bound peptide conformation. The rigid body degrees of freedom and the
peptide rotatable angles were treated as independent variables during molecular docking
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(36–39). Peptide docking with the ensemble of multiple protein structures has allowed to
propose a putative-consensus binding site(s) on the surface of EC5 and to understand the
binding of HAV and BLG4 peptides to the EC5 domain.
RESULTS
EC5 expression and purification
Production and purification of the EC5 domain with and without a Strep-Tag was
straightforward. Initially, the EC5 protein was expressed with a Strep-Tag at the N-terminus
for ease of purification. One-step purification using a Strep-Tactin affinity column produces
a pure EC5 protein with the correct molecular weight and an optimal yield of 0.5 mg/L. The
native EC5 protein without the Strep-Tag was purified using a heat/cool step to remove
other proteins (23). The soluble protein was then subjected to two chromatographic
purification steps. The isolated EC5 protein had a yield of 5–10 mg/L with a final purity
greater than 99% based on reversed-phase HPLC analysis. The production of 15N-labeled
EC5 was similar to that of unlabeled EC5, and a similar high degree of purity was obtained.
Characterization of disulfide bonds
There are four Cys residues in the primary sequence of EC5 that could form two disulfide
bonds as seen in the EC5 domain of C-cadherin (14). To test whether the Cys residues form
such disulfide bonds, the content of free thiol groups in the EC5 protein was analyzed using
the ThioGlo-1 reagent (40). There was no difference between the blank buffer and native
EC5 (not illustrated) after the ThioGlo-1 reaction. This suggests that the over expressed
version of EC5 contains the two predicted disulfide bonds. Upon reduction of the EC5
protein, high fluorescence intensity was observed upon treatment with ThioGlo-1,
suggesting that both disulfide bonds were reduced to free thiol groups quantitatively
(approximate 100%).
Both non-reducing gel electrophoresis and SEC indicated that there was no covalent
dimerization or oligomerization via intermolecular disulfide bond formation. In addition, the
single peak observed in SEC corresponds to a monomeric unit of EC5 based on a calibration
curve using standard proteins. These results also indicate that EC5 does not form
intermolecular disulfide bonds or other physical dimers or oligomers in solution.
Structural studies of EC5 and the effect of disulfide bonds on structural stability
To provide a working model of the structure of the EC5 domain of E-cadherin, a model
structure was generated using the X-ray structure of the EC5 domain of C-cadherin (Figure
1A). The BLAST program was used to align the sequences of the EC5 domains of E- and C-
cadherin; from the alignment study, there are seven high homology regions between the EC5
domains of E- and C-cadherin (data not shown). The degree of identity and similarity
between the two EC5 domains is 57%. Several molecular parameters of EC5 were compared
to those of the EC1 and EC4 domains of E-cadherin (Table 1). The EC1 structure was
determined by X-ray crystallography (6) while the EC4 structure is a model based on the
crystal structure of the corresponding domain of C-cadherin (22). EC5 has the largest
calculated surface area followed by the EC4 and then EC1 domains. EC5 has the lowest
number of H-bonds compared to EC1 and EC4, and the EC1 domain has the greatest
number of H-bonds. These results suggest that EC5 has a less compact structure than EC1 or
EC4. EC5 has only a slightly higher apolar surface area (59%) than hydrophilic surface area
(41%). Although the absolute hydrophobic surface area of EC1 is almost the same as that of
EC5, the percent of hydrophobic area in EC1 (85%) is actually much larger than that of EC5
(59%). In contrast, EC4 has the lowest apolar surface area (20%). All of these parameters
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indicate that, although EC domains have similar overall structures, they differ in several
important structural details that might relate to their multiple functions.
The effect of various solution conditions on the secondary structure of EC5 was evaluated
using CD spectroscopy. EC5 has high β-sheet and β-turn content because E-cadherin
belongs to the immunoglobulin superfamily. An inflection point is observed at 210–215 nm
of the native protein from the β-structure (data not shown). The CD spectrum shows a
positive peak near 230 nm, which probably originates from one or more aromatic residues or
possibly from the disulfide bonds. Upon increasing the temperature, significant spectral
changes at 230 nm were observed between 50 and 70 °C with an estimated melting
temperature (Tm) of 62 °C (Figure 1B). The relatively high melting temperature is
presumably due to the presence of the two intramolecular disulfide bonds that contribute
strongly to the conformational rigidity of EC5. Heating from 20 to 90 °C followed by
cooling back to 20 °C produced identical spectra (see Supplementary Materials), suggesting
that the temperature-induced unfolding is reversible.
Upon reduction of both disulfide bonds in EC5 using DTT, a dramatic change was observed
in the CD spectrum, which suggests significant conformational alteration of the protein. The
positive peak at 230 nm disappeared (Figure 2A), suggesting that the presence of the two
disulfide bonds is important for the structural integrity of the tertiary structure of EC5.
Although the secondary structure of EC5 was not completely restored after removal of DTT
by dialysis, the positive peak at 230 nm reappeared, indicating the possible re-formation of a
significant amount of structure and the disulfide bonds.
The secondary structure and the effect of disulfide bonds on the structure of EC5 were also
evaluated by FTIR and fluorescence spectroscopy. The FTIR spectra show strong amide I
absorption bands at 1630 and 1678 cm−1, signifying that EC5 has a high content of β-sheet
(Figures 2A and B); this is similar to the finding from CD spectroscopy and consistent with
the molecular model (Figure 1). After reducing the disulfide bonds, the IR absorption
spectrum shifted to lower frequency, consistent with an increase in disordered structure
(Figures 2A and 2B). The FTIR spectra of the native and reduced EC5 proteins were
compared to evaluate conformational changes upon reduction (Figure 2B). Upon reduction,
the major negative peaks at 1630 and 1678 cm−1 of native EC5 appear to be shifted to new
peaks near 1619 and 1682 cm−1 for the reduced form. The appearance of a signal near 1619
cm−1 is usually attributed to the presence of intermolecular β-structure. The low correlation
between the two spectra (r = 0.289) indicates a major difference between the secondary
structures of the native and reduced forms (29).
The tertiary structure and thermal unfolding properties of EC5 were evaluated by observing
the intrinsic fluorescence of the single Trp residue. The emission spectrum of the Trp
residue shows a major peak at 320 nm and a shoulder at 332 nm (Figure 2C), suggesting the
presence two different microenvironments of the Trp residue and, consequently, two
different stable conformations. Reduction of the two disulfide bonds present in EC5
dramatically shifts the emission peak of the Trp residue from 320/332 nm to a single peak at
346 nm (Figure 2C), which indicates that the reduced form has a more disordered structure
with the Trp residue more exposed to aqueous solvent. Thermal studies of EC5 show a first
transition with a shift of the major peak at 320 nm to a peak at 332 nm (Figure 3A). Upon
further temperature increase, a second transition was observed with a shift of the peak at 332
nm to a new signal at 346 nm, corresponding to a much greater exposure of the indole side
chain. The effect of temperature on the wavelength of the maxima defines three possible
transition temperatures (i.e., at 35 °C, 55 °C, and 65 °C, Figure 3B).
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The presence of at least two different conformations for EC5 in the fluorescence
experiments was confirmed by differential scanning calorimetry (DSC) (Figure 4).
Deconvolution of the experimental thermograms provides two melting transitions located at
approximately 54.5 and 64.3 °C. These transition temperatures are similar to those found
using fluorescence spectroscopy as shown in Figure 3B, except that the first transition at 35
°C is absent. This suggests that the first transition may be due to a local dynamic effect
rather than a global unfolding transition.
The second derivative UV spectrum of EC5 shows six peaks that are contributed by six
aromatic chromophores (i.e., one Trp, two Tyr, and three Phe residues) (Figure 5A). The
second derivative UV spectra can be used to probe the effect of environmental changes on
EC5 conformation around the aromatic residues (41–43). Peaks 1, 2, and 3 could possibly be
due to the three Phe residues. Peak 4 could possibly be derived from the two Tyr residues
while peak 5 could represent a joint contribution from the Tyr and Trp residues. Peak 6
could be generated by the single Trp residue alone. The effect of temperatures on the
wavelength of peaks 5 and 6 (Figure 5B) shows typical melting curves for thermal unfolding
with a melting temperature of 65 °C as also seen by CD and fluorescence spectroscopy.
These peaks exhibit blue shifts during the thermal unfolding process, indicating that the Trp
and Tyr residues are more exposed to the aqueous solvent at higher temperatures. The lower
wavelength peaks (i.e., peaks 1–4) display a much smaller spectral change upon temperature
elevation. This is no doubt due to the nature of the Phe residues, which are buried in the
more hydrophobic interior regions of the protein and therefore do not undergo dramatic
changes in the polarity of their environment (30). Thus, it appears that the core structure
remains in EC5 even at high temperature. This is also consistent with the less than complete
shifting of the Trp residue to a completely exposed state. This is expected due to the
presence of the disulfide bonds that prevent complete unfolding. In the reduced state of the
protein, both peaks 5 and 6 lose their distinctive melting curves (Figure 5C).
1H-15N-HSQC NMR spectra also imply the presence of multiple conformations of the EC5
protein. At 30 °C, the NMR spectrum of EC5 shows good dispersion of cross-peaks between
8.5 and 10 ppm, indicating a well-folded protein (Figure 6A); however, more than 200 peaks
are observed. The expected number of peaks in the HSQC spectrum is 135 because EC5 has
116 residues with 11 Pro and 15 Asn/Gln. The higher number of peaks compared to the
expected number suggests the presence of multiple conformers. In addition, the indole ring
NH of the only Trp residue gives two distinct peaks (9.96/128.52 ppm for 1H/15N and
9.92/128.4 ppm for 1H/15N) at low temperature (see arrows on Figure 6A). The NMR
spectrum is simplified upon heating to 65 °C as the protein partially unfolds and the Trp
indole NH displays only a single resonance (see arrow in Figure 6B). The chemical shifts of
the side chains of Asn and Gln are also collapsed into a single pair of peaks around 6.6/7.3
ppm for the 1H and 111 ppm for the 15N upon structural disruption at 65 °C (Figure 6B).
When the protein is cooled to 30 °C or 40 °C for about 30 min, the NMR spectrum returns to
its original state, suggesting that the protein can be refolded to the original structure (see
Supplementary Materials). In this case, previous NMR studies (data not shown) indicated
that the EC5 conformation does not change significantly within the pH range of 5.0 to 7.5.
Thus, the spectral difference between 30 °C and 65 °C is not induced by the potential
change of pH.
The NMR data concur with the fluorescence spectroscopy results and are consistent with the
hypothesis that the protein exists in two distinct conformations. NMR is well-suited for
detecting dynamical properties and changes in dynamics. Movements that occur on a fast
timescale relative to data acquisition generate an averaged peak, whereas more than one
peak may emerge from the same residue when exchange is slow. It appears that at least two
sets of resonances are present in the spectra of EC5 at lower temperatures, as peaks having
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distinctly different intensities are apparent (Figure 6). Many peaks, particularly those in
unique chemical shift positions, appear to be doubled, reflecting a major and a minor
population for each pair. Despite a difference in signal strength, the linewidths for the two
populations are similar, suggesting either that the conversion between states is slow or that
two slightly different forms of the protein are present in the sample, as would be the case if
disulfide bond mixing occurred. When the protein is examined at 65 °C, the linewidth
sharpens, reflecting the increased mobility of individual residues in the unfolded state.
However, retention of a few peaks above 8.5 ppm, indicates that the structure of EC5 has not
become a completely random coil. The peak at 10 ppm is generated by the Trp indole, but
the other peaks, particularly the peak at 9.3 ppm, likely correspond to backbone amides near
the disulfide bonds, where the local structure is better preserved at elevated temperatures.
Although intensive analyses can provide residue-specific information in well-behaved
systems, only a cursory analysis of the peak-width was used to assess the structural integrity
of EC5 due to the complexity of the spectrum.
In an attempt to convert EC5 to a single conformation for NMR structural studies, various
solution conditions were investigated, including alterations in pH, buffers, and salt
concentration (data not shown). Addition of KCl or CaCl2 or a change to low pH improved
the NMR spectra and, in some cases, enhanced the signal-to-noise ratio; unfortunately, none
of these changes resulted in convergence to a single set of peaks. Thus, complete assignment
of the resonances and site-specific dynamics analysis remain difficult at this time.
Binding studies of the HAV and BLG4 peptides to EC5 using NMR and FTIR
The interactions of the HAV and BLG4 peptide with 15N-labeled EC5 were investigated
using 1H-15N-HSQC NMR experiments. There are two clusters of peaks at 6.8/112.5 and
7.5/112.5 ppm, which originate from the NH2 groups of the side-chains of the Asn and Gln
residues. Each side-chain generates two peaks in the HSQC spectrum with distinct 1H but
identical 15N chemical shifts. This occurs because the peaks emanate from each of the
two 1H atoms attached to the same 15N atom. These peak clusters suggest that the side-
chains of the Asn and Gln residues are solution exposed and in virtually identical chemical
environments. This makes them difficult to distinguish from each other. Adding the HAV
peptide to 15N-labeled EC5 induces a change in its HSQC spectrum, causing the appearance
of two new peaks at 7.55/108.85, and 7.15/108.85 ppm (see the red arrows in Figure 6C).
These peaks are separated from the clusters at 6.8/112.5 and 7.5/112.5 ppm. Because
changes in the chemical shifts reflect changes in the environment when the environment
around an atom is altered by reducing its exposure to solvent/solution or participating in
hydrogen bonds, these two shifted peaks suggest that one of the Asn or Gln residues might
be interacting with the HAV peptide and altering the chemical shift of a side-chain NH2
group. In addition, the intensity of one of the NH indole peaks of EC5 (9.96/128.5 ppm)
decreases in the presence of the HAV peptide. These changes may be due to a change in the
conformation of EC5 upon binding to the HAV peptide.
Addition of the BLG4 peptide to 15N-labeled EC5 causes even more dramatic changes in the
spectrum of EC5 (data not shown). The overall spectrum of EC5 is simplified significantly
in the presence of the BLG4 peptide, i.e., addition of this peptide substantially reduces the
total number of peaks from 252 to 161. The two peaks of the NH indole ring from the single
Trp residue (9.96/128.5 and 10.08/129.5 ppm) merge into one peak at 10.1/129.4 ppm in the
presence of the BLG4 peptide. These results suggest that binding of BLG4 to EC5 stabilizes
one of the two equilibrium conformations of EC5. In addition, two peaks from the NH2 side-
chain of one of the Asn or Gln residues are again shifted from the original clusters at
6.8/112.5 and 7.5/112.5 ppm on EC5 alone to 7.37/107.3 and 7.09/107.3 ppm in the
complex. Thus, like the HAV peptide, BLG4 may also bind to EC5 in a region containing an
Asn and/or Gln residue.
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13C,15N-double-labeled EC5 was also used to determine the binding properties of HAV and
BLG4 peptides to EC5. The presence of heavier isotopes (i.e., 13C or 15N) in double-labeled
EC5 shifts the amide I band to a lower frequency (44) from the band of unlabeled EC5 with
the assumption that both of the labeled and unlabeled EC5 have identical conformations.
The FTIR amide I bands unlabeled EC5, double-labeled EC5, and a mixture of double-
labeled EC5 and the peptides were analyzed to determine the effects of peptide binding on
EC5 (Figure 7). The amide I band of unlabeled EC5 was shifted from 1637 cm−1 to 1594
cm−1 in the double-labeled EC5 (Figure 7A). Addition of the unlabeled HAV or BLG4
peptide to double-labeled EC5 altered the amide I band. Deconvolution of the amide I band
of the unlabeled EC5 resolves several bands, including the 1608 cm−1 and 1585 cm−1
signals (Figures 7A–D). Both of these bands were used to estimate the amount of α-helix
and β-sheet in EC5, respectively (Table 2) (45). Unfortunately, unambiguous assignments
for the other peaks are unavailable. The estimated amount of α-helical structure in EC5 was
increased from 13% to 22% and 24% upon binding to HAV and BLG4, respectively
(Figures 7C and D; Table 2). A small decrease in β-sheet structure in EC5 was also observed
when binding to either peptide. A new band was seen at 1676 cm−1 in the spectrum of the
mixture of EC5 and BLG4; this band is presumably derived from the β-sheet structure of the
BLG4 peptide itself (46). Thus, upon binding to EC5, the BLG4 peptide also appeared to
change its conformation from disordered to β-sheet structure.
DISCUSSION
The structure and dynamic properties of EC5 may play an important role during the
homophilic and heterophilic interactions of E-cadherin; therefore, the structural and binding
properties of EC5 were investigated. Based on SEC, EC5 exists in a monomeric form with
two intramolecular disulfide bonds, which play an important role in the structural stability of
EC5 (47, 48). Reducing these disulfide bonds lowers EC5 structural stability, and the change
in EC5 conformation is reflected in the disappearance of the CD positive peak at 230 nm,
which is due to a combination of different structural features (i.e., β-turns, aromatic
residues, and disulfide bonds). The second derivative FTIR spectrum of the reduced form
has a new absorption band at 1619 cm−1 (Figure 2B), which suggests the presence of some
intermolecular β-sheet structure, perhaps produced by aggregation. In addition, reduction of
the disulfide bond shifts the fluorescence λmaxEM from a dual peak at 320 and 332 nm to a
single signal at 346 nm, indicating a dramatic change in the tertiary structure of EC5 (Figure
2C). The fluorescence λmaxEM at 346 nm of reduced EC5 is much closer to the λmaxEM of
free indole (typically 350–355 nm) in water, and is similar to that of the thermally disrupted
form of EC5. In summary, the relatively high thermal stability of EC5 probably is due to the
existence of the two intramolecular disulfide bonds.
The fluorescence and NMR spectroscopy data suggest the presence of two distinct EC5
conformations. Although EC5 contains only one Trp residue, the intrinsic fluorescence of
this residue showed two peaks at 320 and 332 nm at room temperature. These two peaks
merged into a single peak at 332 nm during temperature elevation and, finally, the peak
shifted to 346 nm upon further unfolding at high temperature (Figure 3A). The existence of
two conformers is also indicated by the presence of two indole ring NH cross-peaks in
the 1H-15N-HSQC NMR spectrum at 30 °C in the 15N-labeled protein (Figure 6A). At 65
°C, these two cross-peaks collapsed to a single cross-peak at 9.95 and 129 ppm for 1H
and 15N resonances, respectively (Figure 6B). The two DSC transitions observed at 54.5 °C
and 64.3 °C also support the possible presence of two different stable conformation of EC5
(Figure 4).
Typically, the interpretation of the observed spectroscopic and calorimetric data would
support two possible mechanisms (A and B, Figure 8) for the conformational change in EC5
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upon temperature increase. Mechanism A suggests the presence of two conformations (C1
and C2) at room temperature. As the temperature increases, C1 converts to a more stable C2
conformation at 54.5 °C. Conformation C2 then unfolds at a melting temperature of 64.3 °C.
Mechanism B postulates the existence of three different conformational states (C1, C2, and
C3); at room temperature, EC5 exists in two conformations, C1 and C2. As the temperature
is increased, both the C1 and C2 states convert to C3 at 54.5 °C, and C3 is the intermediate
state prior to unfolding. Conformation C3 unfolds more extensively at 64.3 °C.
In support of mechanism A, the Trp intrinsic fluorescence peaks at 320 and 332 nm can be
assigned to the C1 and C2 conformations, respectively. Increasing the temperature shifts the
peak at 320 nm to the peak at 332 nm, reflecting the conversion of conformation C1 to C2.
Thus, most of the molecules in C1 have converted to C2 at 54.5 °C. As the temperature
reaches 64.3 °C, the C2 conformation is more unfolded. The two conformations (C1 and C2)
of EC5 at room temperature are also reflected by the presence of the two NH indole cross-
peaks with chemical shifts of 9.96/128.52 ppm (C1) and 9.92/128.4 ppm (C2) in the 1H/15N
HSQC spectrum. At 60 °C, these two cross-peaks merge into one cross-peak at 9.95/129
ppm for 1H/15N nuclei. Although the proton resonance (9.95 ppm) of this final cross-peak is
similar to the proton resonance of the C2 conformation at room temperature, the 15N
resonance (129 ppm) more closely resembles the 15N resonance of C1 (129.2 ppm). Thus,
the NMR results cannot completely rule out the possibility of Mechanism B. To explain the
data in terms of Mechanism B, the intrinsic fluorescence peaks at 320 and 332 nm would
represent C1 and C2, respectively, similar to Mechanism A. Furthermore, a low-temperature
transition at 35 °C was observed in the fluorescence spectra (Figure 3B), which suggests the
possible existence of C1 and C2 at low temperature. Upon increases in temperature above
54.5 °C, both C1 and C2 are converted to C3. In this case, the intrinsic fluorescence of the
Trp residue of C3 is similar to that of C2. As mentioned above, the final chemical shift of
the NH indole of the Trp residue may resemble that of an intermediate between those NH
groups of the C1 and C2 states, suggesting the presence of C3. Therefore, it is difficult to
conclusively differentiate between the two mechanisms.
It is not yet clear whether these two conformations are present in the intact E-cadherin
molecules and if they are involved in the function of E-cadherin in its role of mediating cell-
cell adhesion. It is known, however, that the entire extracellular domain of E-cadherin forms
a globular structure in the absence of calcium and a rod-like unit in its presence. It is
possible that the two different conformations of EC5 may be involved in the conversion
between the globular and rod-like structures upon addition of calcium. The interconversion
between these two conformers could also be involved in the cis- and trans- interactions of E-
cadherin during the cell-cell adhesion process. In another cell adhesion receptor, lymphocyte
function-associated antigen 1 (LFA-1), the I-domain of its α-subunit can convert between
“open” and “closed” forms upon binding to its ligands (i.e., allosteric inhibitors) (49).
One of the goals of this project was to search for small peptides (i.e., hexapeptide or smaller)
with good biological activity to modulate the intercellular junctions. The HAV hexapeptide
was discovered by initially examining a large peptide of 24 amino acid residues (24-mer)
that includes the His-Ala-Val (HAV) sequence derived from the groove region of the EC1
domain (50). The 24-mer peptide was reduced to several decapeptides with overlapping
sequences; one of the decapeptides, HAV10 (Ac-LFSHAVSSNG-NH2), containing the His-
Ala-Val sequence was found to have the best ability to inhibit E-cadherin-mediated cell-cell
adhesion (50). Finally, HAV10 was reduced to several hexapeptides and one of these, HAV
(Ac-SHAVSS-NH2), was more effective than the others (20).
The BLG4 peptide sequence was found by homology study between the EC1 and EC4 of E-
cadherin; it was from the bulge region of EC4 similar to the ADT peptide from EC1 (51).
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BLG4 was also found to inhibit E-cadherin-mediated cell-cell adhesion and the resealing of
intercellular junctions of Caco-2 cell monolayers.
The binding properties of the HAV and BLG4 peptides to the EC5 domain were evaluated
using NMR and FTIR. Both peptides induce a dramatic shift of the double-labeled EC5
amide I band (about 43 cm−1 to a lower frequency), suggesting structural changes in EC5
upon peptide binding (44). The β-sheet structure (i.e., the 1676 cm−1 band) of BLG4 was
detected when a complex is formed between BLG4 and EC5. In contrast, no new amide I
signal was observed in the complex between HAV and EC5, suggesting no major structural
change in HAV during binding. The apparent difference in secondary structural change seen
between HAV and BLG4 during binding may also be related to the different binding modes
of each peptide. Although both peptides bind to EC5, it is still possible that these peptides
bind to other EC domains as well (i.e., EC1 to EC4) during the inhibition of E-cadherin-
mediated cell-cell adhesion; thus, the potential interaction between the peptides and other
EC domains will also be examined.
NMR spectroscopy indicates that EC5 changes its tertiary structure when it binds to each
peptide. The two HSQC spectra of EC5 in the presence of HAV or BLG4 are very distinct
from each other. The total peak number compared to that of EC5 alone (252) is increased
upon HAV addition (284) but decreased by BLG4 addition (161). In addition, a distinct new
isolated peak pair from either Asn or Gln is observed in each spectrum upon peptide
addition (i.e., they do not display the same chemical shifts). This alone does not establish
that the peptides bind to different sites on EC5, but, in light of the numerous other changes,
it may indicate that different residues are involved. In the case of BLG4 binding, the two
conformations of EC5 merge into a single structure (data not shown), as shown by the
behavior of the resonances of the NH-indole ring of the Trp residue of EC5. Combined with
the FTIR results, this suggests that both BLG4 and EC5 have to change their conformations
significantly during complexation. During binding of HAV to EC5, the increased intensity
of the NMR peaks at 7.55/115.9 and 7.7/123.7 ppm and the appearance of a new peak at
8.2/109.6 ppm suggest a possible small increase in α-helical content (Figure 6C), which is
consistent with the statistically marginal FTIR results.
Molecular docking simulations were carried out to evaluate the interaction between the
HAV peptide and EC5. The HAV peptide binds to EC5 with a favorable binding energy
(Figures 9A and B) with a network of interactions, including: (i) a hydrogen bond between
the backbone carbonyl oxygen of Ser-5 on the peptide and the amide side-chain of the
Asn-46 residue on EC5; (ii) a hydrogen bond between the carbonyl group of Asn-46 and the
side-chain hydroxyl group of Ser-6 on the peptide; (iii) two hydrogen bonds from both the
side-chain oxygen and the NH backbone of the Ser-1 residue with the side-chain
carboxyamide of Asn-75; (iv) a hydrogen bond between the backbone carbonyl oxygen of
Ser-1 and the amide side-chain of Asn-75; and (v) a hydrogen bond between the backbone
NH group of Ala-3 on the peptide and the backbone carbonyl oxygen of His-41 on EC5. Our
previous Ala scanning experiment also indicated that both Ser-5 and Ser-6 have an
important role in the activity of the HAV peptide (20).
In a similar manner, molecular docking simulations of BLG4 to EC5 identified a structurally
consistent binding pose of the bound peptide that interacts with both the bulge and groove
regions of EC5 (Figures 9C and D). The results indicated a larger degree of structural
change upon BLG4 than HAV binding; the backbone and side-chain of the bulge and groove
regions fluctuate with a root mean square deviation (RMSD) of up to 1.5 Å from the initial
structure. The BLG4 peptide binds to EC5 in an extended structure with the β-sheet
conformation forming another extensive hydrogen-bond network (Figure 9D). In particular,
these interactions include numerous favorable contacts between BLG4 and Asn-46 on EC5:
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(i) hydrogen bonds formed by the carbonyl oxygens of the BLG4 Arg-6 and Asp-7
backbone with the amide group of the Asn-46 side-chain; and (ii) hydrogen bonding
between the hydroxyl group of the BLG4 Thr-8 side-chain and the carbonyl oxygen of the
side-chain of Asn-46 in EC5. These interactions are further strengthened by additional
hydrogen bonds between: (i) the Arg-6 guanidine side-chain of BLG4 with the Glu-38
carboxylic side-chain and the Leu-39 backbone carboxyl oxygen of EC5; and (ii) the Thr-1
side-chain of BLG4 and the amino group of the Lys-77 side-chain on the groove region of
EC5. This model also supports the FTIR data in which BLG4 forms a stable β-sheet
conformation when it binds to EC5 as well as the NMR data that show BLG4 binds to EC5
in a region containing an Asn residue, (i.e., Asn-46).
In conclusion, we have shown that EC5 appears to have at least two different stable
conformations with high thermal stability. The presence of disulfide bonds is essential to
maintaining its conformational and thermal stability. The HAV and BLG4 peptides bind to
EC5, which induces a conformational change in EC5. Molecular modeling studies suggest
that HAV and BLG4 bind to a common bulge region but have distinct groove region
interactions. Using the results from this study, we will attempt to design small peptides that
have higher binding affinity to EC5 than the parent peptides investigated here (i.e., HAV
and BLG4) for enhancing drug permeation through the intestinal mucosa and the blood-
brain barrier.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(A) A molecular model of the EC5 domain of E-cadherin derived from the EC5 domain of
C-cadherin. The four Cys residues form two intramolecular disulfide bonds. (B) The melting
temperatures of the EC5 domain measured by relative molar ellipticity change as a function
of temperature in 25 mM phosphate buffer at pH 7.5 at 230 nm. Data are normalized to the
ME value at 10 °C.
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Comparison of the FTIR and fluorescence spectra of EC5 in the absence and presence of 2.5
mM DTT. (A) The amide-1 FTIR spectra of EC5 in the native (black line) or reduced (red
line) forms. (B) The second derivative FITR spectra of EC5 in the native (black line) and
reduced (red line) forms. (C) Comparison between the emission peaks of the native EC5
(solid line) and reduced EC5 (dashed line).
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EC5 tertiary structure monitored by intrinsic fluorescence spectra. (A) The temperature-
dependent shift of the fluorescence emission peak from the Trp residue at 0.02 mM EC5 in
25 mM phosphate buffer at pH 7.5. (B) The change in emission wavelengths of the same
EC5 as a function of temperature.
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Thermally induced unfolding of 0.1 mM EC5 in 25 mM phosphate buffer at pH 7.5
monitored by DSC.
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EC5 tertiary structure monitored by second derivative UV spectra. (A) 0.02 mM EC5 in 25
mM phosphate buffer at pH 7.5. (B) The effect of temperature on the wavelengths of two
aromatic residues (peaks 5 and 6) of native EC5. (C) The effect of temperature on peaks 5
and 6 of the aromatic residues from the reduced form of EC5.
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EC5 tertiary structure monitored by NMR with arrows indicating the resonance(s) for the
indole NH of the Trp residue. The 1H-15N HSQC NMR spectrum of 0.5 mM EC5 domain in
25 mM Tris buffer with 10% D2O in pH 7.5 at (A) 30 °C and (B) 65 °C. 1H-15N-HSQC
NMR spectrum of 0.2 mM 15N labeled EC5 in 100 mM Tris buffer containing 5% D2O at
pH 7.5 and room temperature. (C) EC5 in the presence of 20 mM HAV peptide. The red
arrows indicate the chemical shift changes seen after peptide binding. (D) The NMR
spectrum of EC5 upon addition of 10 mM BLG4 peptide and the chemical shift changes
upon peptide addition are indicated by red arrows.
Zheng et al. Page 32













Zheng et al. Page 33













Zheng et al. Page 34













Zheng et al. Page 35














(A) 0.5 mM unlabeled or 13C and 15N double-labeled EC5 in the absence or presence of 50
mM HAV or 25 mM BLG4 peptides in 100 mM Tris-D2O buffer at pH 7.5 and room
temperature. (B) Deconvolution of the amide I band of 13C and 15N double-labeled EC5 in
the absence of peptide. (C) Deconvolution of the amide I band of 13C and 15N double-
labeled EC5 in the presence of HAV peptide. (D) Deconvolution of the amide I band of 13C
and 15N double-labeled EC5 in the presence of BLG4 peptide.
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Proposed multiple conformations of EC5 and their pathways of structural alteration upon
increases in temperature.
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(A) The predicted conformation of the HAV peptide bound to the homology modeled
structure of the EC5 domain of E-cadherin. (B) A close-up of the hydrogen bond network
formed by the HAV peptide bound to EC5. (C) The predicted conformation of the BLG4
peptide bound to EC5. (D) A close-up of the hydrogen bond network formed by the
BLG4 peptide bound to EC5.
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Table 1
Comparison of several molecular parameters of the EC1, EC4, and EC5 domains.
EC1 EC4 EC5
Atom number 837 851 932
aHydrophilic surface area 914 Å2 (15%) 5217 Å2 (80%) 3451.0 Å2 (41%)
aHydrophobic surface area 4998 Å2 (85%) 1268 Å2 (20%) 5045.7 Å2 (59%)
Total molecular surface area 5913 Å2 6485 Å2 8496.7 Å2
H-bond number 70 47 35
a
The numbers in parentheses are the percent of hydrophilic or hydrophobic surface areas compared to the total surface area of each EC domain.
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Table 2
Secondary structure changes of 0.5 mM 15N and 13C double-labeled EC5 after addition of 50 mM HAV or 25
mM BLG4 in 100 mM Tris-D2O buffer at pH 7.5 and room temperature.
α-helix β-Sheet
EC5 13% ± 5% 34% ± 7%
EC5 + HAV 22% ± 2% 32% ± 3%
EC5 + BLG4 24% ± 7% 26% ± 5%
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